Sodium-glucose co-transporters (SGLT2) inhibitors prevent lipid droplets formation in vascular inflammation or lipid overload by SGLT2-independent mechanism
This is the first report demonstrating that SGLT2-I prevent the formation of LDs in the vasculature. Empagliflozin downregulates LDs formation in vascular inflammation or lipid overload via an SGLT2-independent mechanism. Empagliflozin's protective effects involve the NHE1/PKC/NOX pathway in the TNF response but not in the OA response.
Authors
- Kamila Wojnar‐Lason (ORCID: https://orcid.org/0000-0002-9884-2032)
- Diane Bakker
- Coert J. Zuurbier (ORCID: https://orcid.org/0000-0001-8361-2448)
- Natalia Chorazy (ORCID: https://orcid.org/0000-0001-8597-0206)
- Marta Z. Pacia (ORCID: https://orcid.org/0000-0002-0391-2502)
- Stefan Chłopicki (ORCID: https://orcid.org/0000-0002-2878-3858)
- Anna M. Gdula (ORCID: https://orcid.org/0000-0001-8241-1185)
Institutions
- Jagiellonian University (PL)
- Amsterdam Neuroscience (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1016/j.biopha.2025.117967
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47
Funders
- Narodowe Centrum Nauki
- Narodowym Centrum Nauki